Abstract
Dengue fever is a type of disease with a high and fast transmission rate, especially in tropical and subtropical regions. One of the dengue fever vaccines developed by Sanofi Pasteur (CYD-TDV) and has undergone phase III clinical trials is the tetravalent dengue vaccine. This study aims to conduct a meta-analysis and review analysis of the effectiveness of the dengue vaccine on the level of efficacy at various age levels based on previously published research results. This research uses a quantitative approach through a meta-analysis study. The data in this study were obtained from multiple sources of scientific literature in the form of research articles published in national and international journals. Data was collected online through Google Scholar, PubMed, ProQuest, Cochrane Library, and Scopus—a literature search from various sources using the keyword dengue vaccine. Data analysis was performed with the distinct stages of the study sample, effect size heterogeneity testing, calculating summary effects, calculating p-values, and determining and plotting publication bias/trim-fill analysis. The research results showed that administration of the tetravalent vaccine (CYD-TDV) to children aged 2-16 years had a moderate relationship with a Random Effect value (r ̅_RE)=0.400. The efficacy level of the CYD-TDV dengue vaccine significantly impacts patients who are given the vaccine regularly at certain time intervals (I2=4.46%).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
